文献速递肝病

失代偿期肝硬化与慢加急性肝衰竭(ACLF)防治及生物标志物作用的最新进展

Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers.
PubMed 文献 · Gut · 2024-05-10

综述失代偿期肝硬化向慢加急性肝衰竭(ACLF)进展的机制与防治进展,重点讨论肠源性全身炎症和肝硬化相关免疫功能障碍(CAID)作为创新治疗靶点,以及生物标志物发现和个体化治疗方面的进展。

要点

  • 肝硬化伴临床显著门静脉高压向失代偿期进展仍是临床难题,进展为ACLF伴一个或多个肝外器官衰竭与极高死亡率相关。
  • 门静脉高压进展时,肠道屏障受损致细菌易位,最终引起内毒素血症、全身炎症和肝硬化相关免疫功能障碍(CAID)。
  • 肠源性全身炎症和CAID已成为预防肝硬化失代偿发作及向ACLF进展的创新治疗靶点,疾病分类和生物标志物发现推动个体化诊疗。

核心结论

  • 肠源性全身炎症和CAID已成为预防肝硬化失代偿发作及向ACLF进展的创新治疗合理靶点,生物标志物发现与疾病分类推动失代偿期肝硬化和ACLF的个体化诊疗。

研究设计与样本

  • 综述,讨论失代偿期肝硬化和ACLF中生物标志物发现与治疗个体化的进展。

主要发现

  • 门静脉高压进展时,肠道屏障受损致细菌易位,最终引起内毒素血症、全身炎症和肝硬化相关免疫功能障碍(CAID)。
  • 肝硬化伴临床显著门静脉高压向失代偿期进展仍是临床难题,进展为ACLF伴一个或多个肝外器官衰竭与极高死亡率相关。
  • 过去十年对失代偿和ACLF发生机制的理解取得显著进展。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The progression of cirrhosis with clinically significant portal hypertension towards decompensated cirrhosis remains clinically challenging and the evolution towards acute-on-chronic liver failure (ACLF), with one or more extrahepatic organ failures, is associated with very high mortality. In the last decade, significant progress has been made in the understanding of the mechanisms leading to decompensation and ACLF. As portal hypertension advances, bacterial translocation across an impaired gut barrier culminates in endotoxaemia, systemic inflammation and cirrhosis-associated immune dysfunction (CAID). Gut-derived systemic inflammation and CAID have become the logical targets for innovative therapies that prevent hepatic decompensation episodes and the progression to ACLF.Furthermore, classification of disease and biomarker discovery to personalise care have advanced in the field. This review discusses progress in biomarker discovery and personalisation of treatment in decompensated cirrhosis and ACLF.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Trebicka J, Hernaez R, Shawcross DL, et al. Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers. Gut. 2024. PMID: 38527788. doi:10.1136/gutjnl-2023-330584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。